Nociceptors in cardiovascular functions: Complex interplay as a result of cyclooxygenase inhibition

Molecular Pain

Volumn 2, Issue , 2006, Pages

  Premkumar, Louis S ^a   Raisinghani, Manish ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

20 HYDROXYICOSATETRAENOIC ACID; ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CALCIUM ION; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYTOCHROME P450; EPOXYICOSATRIENOIC ACID; HYDROXYICOSATETRAENOIC ACID; ION CHANNEL; LEUKOTRIENE B4; LEUKOTRIENE E4; NAPROXEN; PROSTACYCLIN; PROSTAGLANDIN; PROSTAGLANDIN D2; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN SYNTHASE INHIBITOR; THROMBOXANE A2; VANILLOID RECEPTOR 1; VASOACTIVE AGENT;

ANALGESIC ACTIVITY; ARACHIDONIC ACID METABOLISM; ARTICLE; BLOOD VESSEL INNERVATION; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CHEMOSENSITIVITY; DOSE RESPONSE; ENZYME INHIBITION; ENZYME SPECIFICITY; ENZYME SYNTHESIS; FATTY ACID SYNTHESIS; GASTROINTESTINAL TOXICITY; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART INNERVATION; HEART MUSCLE ISCHEMIA; HEAT SENSITIVITY; HUMAN; MECHANOTRANSDUCTION; NERVE ENDING; NEUROTRANSMITTER RELEASE; NOCICEPTION; NOCICEPTIVE RECEPTOR; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; RISK ASSESSMENT; SENSORY NERVE; SENSORY NERVE CELL; SIDE EFFECT; STROKE; SYNAPTIC POTENTIAL; SYNAPTIC TRANSMISSION; THROMBOCYTE AGGREGATION; THROMBOEMBOLISM; VASOCONSTRICTION; VASODILATATION;

ANIMALS; ARACHIDONIC ACID; CARDIOVASCULAR PHYSIOLOGICAL PHENOMENA; CARDIOVASCULAR SYSTEM; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; GANGLIA, SENSORY; HUMANS; ION CHANNELS; MODELS, BIOLOGICAL; NOCICEPTORS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS; SUBSTRATE SPECIFICITY;

EID: 33748749808     PISSN: 17448069     EISSN: None     Source Type: Journal    
DOI: 10.1186/1744-8069-2-26     Document Type: Article

References (61)

1. Bogatcheva NV, Sergeeva MG, Dudek SM, Verin AD: Arachidonic acid cascade in endothelial pathobiology. Microvasc Res 2005, 69:107-127.
2. Koistinaho J, Chan PH: Spreading depression-induced cyclooxygenase-2 expression in the cortex. Neurochem Res 2000, 25:645-651.
3. McQueen DS, Bond SM, Moores C, Chessell I, Humphrey PP, Dowd E: Activation of P2X receptors for adenosine triphosphate evokes cardiorespiratory reflexes in anaesthetized rats. J Physiol 1998, 507:843-855.
4. Burnstock G: P2X receptors in sensory neurons. Br J Anaesth 2000, 84:476-488.
5. Sutherland SP, Benson CJ, Adelman JP, McCleskey EW: Acid-sensing ion channel 3 matches the acid-gated current in cardiac ischemia-sensing neurons. Proc Natl Acad Sci USA 2001, 98:711-716.
6. Snitsarev V, Whiteis CA, Abboud FM, Chapleau MW: Mechanosensory transduction of vagal and baroreceptor afferents revealed by study of isolated nodose neurons in culture. Auton Neurosci 2002, 98:59-63.
7. Ditting T, Linz P, Hilgers KF, Jung O, Geiger H, Veelken R: Putative role of epithelial sodium channels (ENaC) in the afferent limb of cardio renal reflexes in rats. Basic Res Cardiol 2003, 98:388-400.
8. Maggi CA, Meli A: The sensory-efferent function of capsaicin-sensitive neurons. Gen Pharmacol 1988, 19:1-43.
9. McDonald DM, Bowden JJ, Baluk P, Bunnett NW. Neurogenic inflammation. A model for studying efferent actions of sensory nerves. Adv Exp Med Biol 1996, 410:453-462.
10. Seyedi N, Maruyama R, Levi R: Bradykinin activates a cross-signaling pathway between sensory and adrenergic nerve endings in the heart: a novel mechanism of ischemic norepinephrine release? J Pharmacol Exp Ther 1999, 290:656-663.
11. Moreau ME, Garbacki N, Molinaro G, Brown NJ, Marceau F, Adam A: The kallikrein-kinin system: current and future pharmacological targets. J Pharmacol Sci 2005, 99:6-38.
12. Narumiya S, FitzGerald GA: Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest 2001, 108:25-30.
13. Brain SD, Grant AD: Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiol Rev 2004, 84:903-934.
14. Wang DH: The vanilloid receptor and hypertension. Acta Pharmacol Sin 2005, 26:286-294.
15. Watson RE, Supowit SC, Zhao H, Katki KA, Dipette DJ: Role of sensory nervous system vasoactive peptides in hypertension. Braz J Med Biol Res 2002, 35:1033-1045.
16. Burnstock G: Vascular control by purines with emphasis on the coronary system. Eur Heart J 1989, 10:15-21.
17. Holzer P, Maggi CA: Dissociation of dorsal root ganglion neurons into afferent and efferent-like neurons. Neuroscience 1998, 86:389-398.
18. Hua XY: Tachykinins and calcitonin gene-related peptide in relation to peripheral functions of capsaicin-sensitive sensory neurons. Acta Physiol Scand Suppl 1986, 551:1-45.
19. Julius D, Basbaum AI: Molecular mechanisms of nociception. Nature 2001, 413:203-210.
20. Caterina MJ, Julius D: The vanilloid receptor: a molecular gateway to the pain pathway. Annu Rev Neurosci 2001, 24:487-517.
21. Moriyama T, Higashi T, Togashi K, Iida T, Segi E, Sugimoto Y, Tominaga T, Narumiya S, Tominaga M: Sensitization of TRPV1 by EP1 and IP reveals peripheral nociceptive mechanism of prostaglandins. Mol Pain 2005, 1:3.
22. Morenilla-Palao C, Planells-Cases R, Garcia-Sanz N, Ferrer-Montiel A: Regulated exocytosis contributes to protein kinase C potentiation of vanilloid receptor activity. J Biol Chem 2004, 279:25665-25672.
23. Van Buren JJ, Bhat S, Rotello R, Pauza ME, Premkumar LS: Sensitization and translocation of TRPV1 by insulin and IGF-1. Mol Pain 2005, 1:17.
24. Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sorgard M, Di Marzo V, Julius D, Hogestatt ED: Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 1999, 400:452-457.
25. Ross RA: Anandamide and vanilloid TRPV1 receptors. Br J Pharmacol 2003, 140:790-801.
26. Zahner MR, Li DP, Chen SR, Pan HL: Cardiac vanilloid receptor 1-expressing afferent nerves and their role in the cardiogenic sympathetic reflex in rats. J Physiol 2003, 551:515-523.
27. Scotland RS, Chauhan S, Davis C, De Felipe C, Hunt S, Kabir J, Kotsonis P, Oh U, Ahluwalia A: Vanilloid receptor TRPV1, sensory C fibers, and vascular autoregulation: a novel mechanism involved in myogenic constriction. Circ Res 2004, 95:1027-1034.
28. Wang L, Wang DH: TRPV1 gene knockout impairs postischemic recovery in isolated perfused heart in mice. Circulation 2005, 112:3617-3623.
29. Pan HL, Chen SR: Sensing tissue ischemia: another new function for capsaicin receptors? Circulation 2004, 110:1826-1831.
30. Strecker T, Messlinger K, Weyand M, Reeh PW: Role of different proton-sensitive channels in releasing calcitonin gene-related peptide from isolated hearts of mutant mice. Cardiovasc Res 2005, 65:405-410.
31. Krause JE, Chenard BL, Cortright DN: Transient receptor potential ion channels as targets for the discovery of pain therapeutics. Curr Opin Investig Drugs 2005, 6:48-57.
32. Pedersen SF, Owsianik G, Nilius B: TRP channels: An overview. Cell Calcium 2005, 38:233-252.
33. Alessandri-Haber N, Yeh JJ, Boyd AE, Parada CA, Chen X, Reichling DB, Levine JD: Hypotonicity induces TRPV4-mediated nociception in rat. Neuron 2003, 39:497-511.
34. Yang XR, Lin MJ, McIntosh LS, Sham JS: Functional Expression of Transient Receptor Potential Melastatin- and Vanilloid-Related Channels in Pulmonary Arterial and Aortic Smooth Muscle. Am J Physiol Lung Cell Mol Physiol 2006, 290:L1267-L1276.
35. Freichel M, Vennekens R, Olausson J, Stolz S, Philipp SE, Weissgerber P, Flockerzi V: Functional role of TRPC proteins in native systems: implications from knockout and knock-down studies. J Physiol 2005, 567:59-66.
36. Premkumar LS, Raisinghani M, Pingle SC, Long C, Pimentel F: Downregulation of TRPM8 by Protein Kinase C-mediated dephosphorylation. J Neurosci 2005, 25:11322-11329.
37. Waldmann R, Champigny G, Lingueglia E, De Weille JR, Heurteaux C, Lazdunski M: H(+)-gated cation channels. Ann N Y Acad Sci 1999, 30:67-76.
38. Baron A, Deval E, Salinas M, Lingueglia E, Voilley N, Lazdunski M: Protein kinase C stimulates the acid-sensing ion channel ASIC2a via the PDZ domain-containing protein PICK1. J Biol Chem 2002, 277:50463-50468.
39. Berdiev BK, Xia J, Jovov B, Markert JM, Mapstone TB, Gillespie GY, Fuller CM, Bubien JK, Benos DJ: Protein kinase C isoform antagonism controls BNaC2 (ASIC1) function. J Biol Chem 2002, 277:45734-45740.
40. Leonard AS, Yermolaieva O, Hruska-Hageman A, Askwith CC, Price MP, Wemmie JA, Welsh MJ: cAMP-dependent protein kinase phosphorylation of the acid-sensing ion channel-1 regulates its binding to the protein interacting with C-kinase-1. Proc Natl Acad Sci USA 2003, 100:2029-2034.
41. Allen NJ, Attwell D: Modulation of ASIC channels in rat cerebellar Purkinje neurons by ischaemia-related signals. J Physiol 2002, 543:521-529.
42. Drew LJ, Rohrer DK, Price MP, Blaver KE, Cockayne DA, Cesare P, Wood JN: Acid-sensing ion channels ASIC2 and ASIC3 do not contribute to mechanically activated currents in mammalian sensory neurons. J Physiol 2004, 556:691-710.
43. Page AJ, Brierley SM, Martin CM, Martinez-Salgado C, Wemmie JA, Brennan TJ, Symonds E, Omari T, Lewin GR, Welsh MJ, Blackshaw LA: The ion channel ASIC1 contributes to visceral but not cutaneous mechanoreceptor function. Gastroenterology 2004, 127:1739-1747.
44. North RA: Molecular physiology of P2X receptors. Physiol Rev 2002, 82:1013-1067.
45. Mei Q, Liang BT: P2 purinergic receptor activation enhances cardiac contractility in isolated rat and mouse hearts. Am J Physiol Heart Circ Physiol 2001, 281:H334-H341.
46. Lee YH, Lee SJ, Seo MH, Kim CJ, Sim SS: ATP-induced histamine release is in part related to phospholipase A2-mediated arachidonic acid metabolism in rat peritoneal mast cells. Arch Pharm Res 2001, 24:552-556.
47. Boue-Grabot E, Archambault V, Seguela P: A protein kinase C site highly conserved in P2X subunits controls the desensitization kinetics of P2X(2) ATP-gated channels. J Biol Chem 2000, 275:10190-10195.
48. Vial C, Tobin AB, Evans RJ: G-protein-coupled receptor regulation of P2X1 receptors does not involve direct channel phosphorylation. Biochem J 2004, 382:101-110.
49. Hung AC, Chu YJ, Lin YH, Weng JY, Chen HB, Au YC, Sun SH: Roles of protein kinase C in regulation of P2X(7) receptor-mediated calcium signalling of cultured type-2 astrocyte cell line, RBA-2. Cell Signal 2005, 17:1384-1396.
50. Vulchanova L, Arvidsson U, Riedl M, Wang J, Buell G, Surprenant A, North RA, Elde R: Differential distribution of two ATP-gated channels (P2X receptors) determined by immunocytochemistry. Proc Natl Acad Sci USA 1996, 93:8063-8067.
51. Lee Y, Rodriguez C, Dionne RA: The role of COX-2 in acute pain and the use of selective COX-2 inhibitors for acute pain relief. Curr Pharm Des 2005, 11:1737-1755.
52. Tsujii M, Kawano S, DuBois RN: Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997, 94:3336.
53. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000, 343:520-1528.
54. Romano M, Claria J: Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy. FASEB J 2003, 17:1986-95.
55. Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med 1999, 340:115-126.
56. Belton O, Byrne D, Kearney D, Leahy A, Fitzgerald DJ: Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000, 102:840-845.
57. Catella-Lawson F, McAdam B, Morrison BW, Kapoor S, Kujubu D, Antes L, Lasseter KC, Quan H, Gertz BJ, FitzGerald GA: Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 1999, 289:735-741.
58. Cheng Y, Austin SC, Rocca B, Koller BH, Coffman TM, Grosser T, Lawson JA, FitzGerald GA: Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 2002, 296:539-541.
59. Couzin J: Drug safety. FDA panel urges caution on many anti-inflammatory drugs. Science 2005, 307:1183-1185.
60. Lenzer J: FDA advisers warn: COX 2 inhibitors increase risk of heart attack and stroke. Br Med J 2005, 330:440.
61. Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, D'Agostino RB, Massaro JM, Beiser A, Wolf PA, Benjamin EJ: Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004, 110:1042-1046.